Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EBT (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed EBT for 7 consecutive years, with -$7985.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 68.27% year-over-year to -$7985.0, compared with a TTM value of $22483.0 through Sep 2025, up 117.42%, and an annual FY2024 reading of -$131498.0, down 12.05% over the prior year.
  • EBT was -$7985.0 for Q3 2025 at Goldenwell Biotech, down from -$5220.0 in the prior quarter.
  • Across five years, EBT topped out at $70065.0 in Q4 2024 and bottomed at -$920334.0 in Q4 2022.
  • Average EBT over 5 years is -$68738.2, with a median of -$27084.0 recorded in 2023.
  • The sharpest move saw EBT crashed 16234.25% in 2021, then soared 436.87% in 2024.
  • Year by year, EBT stood at -$29554.0 in 2021, then tumbled by 3014.08% to -$920334.0 in 2022, then surged by 97.74% to -$20799.0 in 2023, then skyrocketed by 436.87% to $70065.0 in 2024, then crashed by 111.4% to -$7985.0 in 2025.
  • Business Quant data shows EBT for GWLL at -$7985.0 in Q3 2025, -$5220.0 in Q2 2025, and -$34377.0 in Q1 2025.